Volume 67, Issue 3, Pages (September 2017)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Depression, anemia and health-related quality of life in chronic hepatitis C Amy A. Dan, Lisa M. Martin, Cathy Crone, Janus P. Ong, Denise W. Farmer, Thomas.
Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
Volume 66, Issue 3, Pages (March 2017)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
Volume 59, Issue 6, Pages (December 2013)
Optimum timing of treatment for hepatitis C infection relative to liver transplantation  Dr Audrey Coilly, MD, Bruno Roche, MD, Prof Jean-Charles Duclos-Vallée,
Primary prevention of variceal haemorrhage: A pharmacological approach
Volume 61, Issue 6, Pages (December 2014)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Volume 51, Issue 6, Pages (December 2009)
The impact of hepatitis E in the liver transplant setting
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Immigration and viral hepatitis
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Volume 66, Issue 1, Pages 1-4 (January 2017)
Volume 69, Issue 1, Pages (July 2018)
Living donor liver transplantation: is the hype over?
Reply to: “DCD consensus and futility in liver transplantation”
Volume 69, Issue 2, Pages (August 2018)
Transplantation for alcoholic liver disease
The place of downstaging for hepatocellular carcinoma
Mauro Bernardi, Stefano Gitto, Maurizio Biselli  Journal of Hepatology 
Reply to: “Low free T3 levels are related to early mortality in patients with decompensated cirrhosis and acute-on chronic liver failure”  Rakhi Maiwall,
Autoimmune hepatitis: A life-long disease
Jordan J. Feld, Graham R. Foster  Journal of Hepatology 
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
Volume 65, Issue 4, Pages (October 2016)
Hepatitis C core protein – The “core” of immune deception?
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Volume 62, Issue 3, Pages (March 2015)
Management of cirrhosis due to chronic hepatitis C
Genomic risk of hepatitis C-related hepatocellular carcinoma
Darius Moradpour, Arash Grakoui, Michael P. Manns 
Volume 49, Issue 4, Pages (October 2008)
Who should get a liver graft?
Volume 44, Issue 4, Pages (April 2006)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Volume 65, Issue 2, Pages (August 2016)
Volume 57, Issue 5, Pages (November 2012)
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Portal vein thrombosis, cirrhosis, and liver transplantation
Immigration and viral hepatitis
Evolution of liver transplantation for hepatocellular carcinoma
Global burden of alcoholic liver diseases
HCV targeting of patients with cirrhosis
Volume 63, Issue 1, Pages (July 2015)
Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection  Isabelle Chemin,
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Volume 66, Issue 3, Pages (March 2017)
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence  Christian Toso, Gilles Mentha, Pietro.
New trials and results in systemic treatment of HCC
Liver transplantation in children
Ana Lleo, M. Eric Gershwin, Alberto Mantovani, Pietro Invernizzi 
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Comment on the article “Age and liver transplantation”
Genetics of hepatocellular carcinoma: The next generation
MELD: the holy grail of organ allocation?
Outcomes in liver transplantation: Does sex matter?
Reversion of disease manifestations after HCV eradication
Presentation transcript:

Volume 67, Issue 3, Pages 585-602 (September 2017) ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients  Luca S. Belli, Christophe Duvoux, Marina Berenguer, Thomas Berg, Audrey Coilly, Isabelle Colle, Stefano Fagiuoli, Saye Khoo, Georges Philippe Pageaux, Massimo Puoti, Didier Samuel, Mario Strazzabosco  Journal of Hepatology  Volume 67, Issue 3, Pages 585-602 (September 2017) DOI: 10.1016/j.jhep.2017.03.006 Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Patients listed for decompensated cirrhosis or HCC. Factors to be taken into account in the decision-making process before DAA treatment. Journal of Hepatology 2017 67, 585-602DOI: (10.1016/j.jhep.2017.03.006) Copyright © 2017 European Association for the Study of the Liver Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.